Add this topic to your myFT Digest for news straight to your inbox
While pandemic risk is low, scientists say urgent investigations into the virus are necessary
An FT special report looking at changes in healthcare, treatments and illness itself
For stretched public health budgets, high-tech treatments are hard to afford but some pre-emptive measures can prove good value
Caseloads of cancer and other illnesses of ageing are forecast to rise steeply in lower income countries
Agriculture department has banned infected cattle from crossing state borders
Wellcome’s John-Arne Røttingen says divisions risk harming action on pandemic responses and ‘superbugs’
Now is not a time for paranoia but there is a case for extreme vigilance
How global warming and deforestation are helping diseases jump from animals to humans and spreading fungal infections, while also fuelling antibiotic-resistant ‘superbugs’. Plus the impact on malaria, Lyme disease and the insurance industry
Damage to habitats and closer contact can help multiple infections jump from wildlife
Environmental change and adaptation risk prompts new research in neglected field
Disease specialists point to shifts in the patterns of mosquito-borne infection
Global warming, flooding and pollution could all help promote evolution of pathogens
Habitat encroachment means more opportunities for animal-to-human infection
Changing climate and human population shifts have spread and strengthened foothold
Research is finding ways to extend animal lifespans but regulators are still wary of treating ageing as a disease
The FT’s fifth annual ranking of the region’s businesses by revenue growth. Plus: outsourcers tap into remote work boom; Shopify targets more growth from bigger clients; Brazil’s alternative to electric vehicles; and Vertex Pharmaceutical’s potential answer to the opioid crisis
With revenues having more than doubled since 2019, to $10bn, US pharma group targets painkillers
Technique devised for Timothy syndrome could open way to therapies for other untreatable conditions
Technique highlights concerns shifting global disease burden as populations age
Pfizer’s Emblaveo to be aimed at some of the most dangerous drug-resistant bacteria
High costs and concerns over efficacy and side effects limit uptake of first treatment as another nears approval
Xi Jinping hopes manufacturing can offset the property slump
Ochre Bio partnering with Germany’s Boehringer Ingelheim on treatments that will harness the organ’s capacity to regenerate
Moderna alleges Pfizer and BioNTech infringed its patents in use of mRNA platform
Research harnesses power of generative artificial intelligence in latest sign of its potential use in medicine
International Edition